Keros Therapeutics, Inc. (KROS) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
0.97
↓-86% vs avg
5yr avg: 6.94
30Y Low6.9·High6.9
P/FCF
3.22
↓-56% vs avg
5yr avg: 7.27
30Y Low7.3·High7.3
P/B Ratio
↓
1.33
↓-61% vs avg
5yr avg: 3.42
30Y Low1.0·High5.6
ROE
↑
19.9%
↓+174% vs avg
5yr avg: -27.0%
30Y Low-186%·High20%
Debt/EBITDA
0.23
+0% vs avg
5yr avg: 0.23
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KROS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Keros Therapeutics, Inc. trades at 4.6x earnings, 48% below its 5-year average of 8.9x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 79%. On a free-cash-flow basis, the stock trades at 3.2x P/FCF, 56% below the 5-year average of 7.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $341M | $771M | $593M | $1.2B | $1.2B | $1.4B | $1.1B | — | — |
| Enterprise Value | $70M | $500M | $52M | $854M | $946M | $1.1B | $829M | — | — |
| P/E Ratio → | 4.63 | 8.85 | — | — | — | — | — | — | — |
| P/S Ratio | 1.40 | 3.16 | 166.94 | 7753.76 | — | 67.92 | — | — | — |
| P/B Ratio | 1.33 | 2.54 | 1.04 | 3.52 | 4.37 | 5.61 | 4.18 | — | — |
| P/FCF | 3.22 | 7.27 | — | — | — | — | — | — | — |
| P/OCF | 3.17 | 7.17 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KROS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Keros Therapeutics, Inc.'s enterprise value stands at 1.0x EBITDA, 86% below its 5-year average of 6.9x. The Healthcare sector median is 14.2x, placing the stock at a 93% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.05 | 14.53 | 5656.39 | — | 56.53 | — | — | — |
| EV / EBITDA | 0.97 | 6.94 | — | — | — | — | — | — | — |
| EV / EBIT | 0.99 | 7.08 | — | — | — | — | — | — | — |
| EV / FCF | — | 4.72 | — | — | — | — | — | — | — |
KROS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Keros Therapeutics, Inc. earns an operating margin of 28.9%. Operating margins have expanded from -112543.7% to 28.9% over the past 3 years, signaling improving operational efficiency. ROE of 19.9% indicates solid capital efficiency. ROIC of 167.9% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.4% | 99.4% | 100.0% | 100.0% | — | 100.0% | — | -73.5% | -1.1% |
| Operating Margin | 28.9% | 28.9% | -5939.0% | -112543.7% | — | -280.5% | — | -105.6% | -16.9% |
| Net Profit Margin | 35.7% | 35.7% | -5277.5% | -101319.2% | — | -292.3% | — | -123.4% | -13.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.9% | 19.9% | -41.5% | -50.2% | -40.2% | -23.3% | -34.6% | -186.3% | -10.5% |
| ROA | 18.2% | 18.2% | -38.0% | -45.2% | -37.3% | -22.4% | -32.4% | -64.3% | -4.9% |
| ROIC | 167.9% | 167.9% | -687.6% | -938.9% | -665.7% | -770.9% | — | — | — |
| ROCE | 15.6% | 15.6% | -45.1% | -53.5% | -43.0% | -22.3% | -34.7% | -94.3% | -10.6% |
KROS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Keros Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.2x, which is very conservative (93% below the sector average of 3.2x). The company holds a net cash position — cash of $287M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.03 | 0.04 | 0.05 | 0.00 | 0.00 | 2.58 | 0.06 |
| Debt / EBITDA | 0.23 | 0.23 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.89 | -0.95 | -0.95 | -0.96 | -0.94 | -1.01 | -11.61 | -1.76 |
| Net Debt / EBITDA | -3.75 | -3.75 | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.55 | — | — | — | — | — | — | -3.29 |
| Interest Coverage | — | — | — | — | -104678.00 | -14182.25 | -7587.83 | -1541.00 | — |
Net cash position: cash ($287M) exceeds total debt ($17M)
KROS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Keros Therapeutics, Inc.'s current ratio of 15.45x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 14.25x to 15.45x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.45 | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | 2.23 |
| Quick Ratio | 15.45 | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | 2.23 |
| Cash Ratio | 14.08 | 14.08 | 20.40 | 13.59 | 16.86 | 19.42 | 37.01 | 1.56 | 2.03 |
| Asset Turnover | — | 0.72 | 0.01 | 0.00 | — | 0.08 | — | 0.91 | 0.36 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 9.53 | 458.15 | 2637.19 | — | 330.44 | — | 33.65 | — |
KROS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Keros Therapeutics, Inc. returns 100.0% to shareholders annually primarily through share buybacks. The earnings yield of 21.6% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 21.6% | 11.3% | — | — | — | — | — | — | — |
| FCF Yield | 31.1% | 13.7% | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 48.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 100.0% | 48.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $38M | $37M | $29M | $25M | $23M | $16M | $9M | $9M |
Peer Comparison
Compare KROS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KROSYou | $341M | 4.6 | 1.0 | 3.2 | 99.4% | 28.9% | 19.9% | 167.9% | 0.2 |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 KRYS | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 SMMT | $11B | -9.5 | — | — | — | — | -270.0% | -288.0% | — |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PTCT | $7B | 10.2 | 6.8 | 9.3 | 95.9% | 49.5% | — | — | 0.5 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
KROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
What is Keros Therapeutics, Inc.'s P/E ratio?
Keros Therapeutics, Inc.'s current P/E ratio is 4.6x. The historical average is 8.9x.
What is Keros Therapeutics, Inc.'s EV/EBITDA?
Keros Therapeutics, Inc.'s current EV/EBITDA is 1.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.9x.
What is Keros Therapeutics, Inc.'s ROE?
Keros Therapeutics, Inc.'s return on equity (ROE) is 19.9%. The historical average is -45.8%.
Is KROS stock overvalued?
Based on historical data, Keros Therapeutics, Inc. is trading at a P/E of 4.6x. Compare with industry peers and growth rates for a complete picture.
What are Keros Therapeutics, Inc.'s profit margins?
Keros Therapeutics, Inc. has 99.4% gross margin and 28.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Keros Therapeutics, Inc. have?
Keros Therapeutics, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.